Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
Recruiting
Phase 1
Phase 2
Interventional Study
Esophageal Carcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 70 (estimated)
- Sponsor
- Anhui Provincial Hospital · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Esophageal squamous cell carcinoma is a common malignancy in China. Although neoadjuvant chemoradiotherapy followed by esophagectomy remains a standard modality for locally advanced esophageal squamous cell carcinoma, esophagectomy followed by postoperative radiotherapy is also prevalent in China. Several retrospective studies demonstrated that postoperative radiotherapy could improve the prognosi…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* 18-75 years old.
* After esophagectomy.
* Confirmation of squamous cell carcinoma by pathological examination.
* Pathological staging of pIIb-IVa.
* Over 12 lymph nodes dissected during surgery.
* ECOG 0-1.
* Signature of inform consent by patients
Exclusion Criteria:
* Youn…
Contacts